Centrum Medyczne MBB-MED Marta Błach-Burek

Verified siteinfo

Poland ul. 11 Listopada 11, 32-590 Libiąż, Poland

1 trial recruiting
Atrial fibrillation · Cardiac failure · Obesity
Adult patients

About Specializations

Centrum Medyczne MBB-MED Marta Błach-Burek in Libiąż, Poland specialises in clinical trials of conditions such as Atrial fibrillation, Cardiac failure, Obesity, Type 2 diabetes mellitus, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Research

Centrum Medyczne MBB-MED Marta Błach-Burek focuses on cardiovascular diseases. Current studies evaluate atrial fibrillation and heart failure with preserved or mildly reduced ejection fraction in individuals affected by obesity. One trial tests whether the novel anticoagulant milvexian can match apixaban in preventing stroke. A second study examines if weekly NNC0487-0111 reduces cardiovascular death and heart‑failure hospitalisations.

Stroke prevention in atrial fibrillation
Evaluation of new oral anticoagulants
Management of HFpEF/HFmrEF with obesity
Assessment of novel heart‑failure therapies

Located in Libiąż, Poland, the site conducts its trials with a dedicated investigator team, contributing to the advancement of cardiovascular care in Europe.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

ul. 11 Listopada 1132-590 LibiążPoland

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 4
Partner status: Verified site

More sites in Libiąż Poland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

3 clinical trials

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S